Status:
TERMINATED
Clonidine as Adjunct to Morphine for Neonatal Abstinence Syndrome
Lead Sponsor:
Hennepin County Medical Center, Minneapolis
Conditions:
Neonatal Abstinence Syndrome
Eligibility:
All Genders
36-45 years
Phase:
PHASE4
Brief Summary
This is a prospective randomized double blinded study comparing the effect on duration of pharmacologic treatment and duration of hospital stay when using clonidine at 12 µg/kilogram/day as an adjunct...
Detailed Description
Neonatal abstinence syndrome (NAS) is an emerging epidemic and has lead to a tremendous increase in cost of medical care. Opioids are the mainstay of treatment for NAS although there are concerns abou...
Eligibility Criteria
Inclusion
- Requiring neonatal intensive care unit (NICU) admission for management of neonatal abstinence syndrome
- Gestational age greater than or equal to 36 weeks
- Less than or equal to 48 hours of treatment with morphine for NAS
Exclusion
- Presence of seizures
- Congenital malformations, genetic syndromes or the presence of TORCH infections
- Major medical problems
- Heart rate and/or blood pressure instability
Key Trial Info
Start Date :
April 30 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 12 2018
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT03762317
Start Date
April 30 2018
End Date
December 12 2018
Last Update
February 10 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hennepin County Medical Center
Minneapolis, Minnesota, United States, 55415